Parallax Volatility Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Parallax Volatility Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,173	Closed	-$1.72M	–	3129
2022 Q3	$1.72M	Buy	16,173 +2,481	+18%	+$252K	﹤0.01%	1499
2022 Q2	$1.33M	Buy	13,692 +2,135	+18%	+$197K	﹤0.01%	1533
2022 Q1	$1.08M	Buy	+11,557	New	+$979K	﹤0.01%	1624
2021 Q4	–	Sell	-20,965	Closed	-$2.01M	–	2170
2021 Q3	$2.01M	Buy	20,965 +17,226	+461%	+$1.63M	﹤0.01%	1121
2021 Q2	$364K	Sell	3,739 -6,243	-63%	-$598K	﹤0.01%	1211
2021 Q1	$971K	Buy	9,982 +6,359	+176%	+$667K	﹤0.01%	838
2020 Q4	$347K	Buy	3,623 +3,166	+693%	+$306K	﹤0.01%	1735
2020 Q3	$44K	Buy	+457	New	+$52.9K	﹤0.01%	2865
2019 Q4	–	Sell	-1	Closed	–	–	2563
2019 Q3	$0	Buy	+1	New	+$93	﹤0.01%	3062
2019 Q1	–	Sell	-1,813	Closed	-$152K	–	3580
2018 Q4	$129K	Buy	+1,813	New	+$174K	﹤0.01%	1868
2018 Q1	–	Sell	-2,091	Closed	-$177K	–	3548
2017 Q4	$162K	Buy	+2,091	New	+$143K	﹤0.01%	2446

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parallax Volatility Advisers's NBIX Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 16,173 shares — an estimated $1.72M sold.

Parallax Volatility Advisers first reported a position in NBIX in Q4 2017 and held it in 11 quarters. The position peaked at $2.01M in Q3 2021. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Parallax Volatility Advisers reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 16,173 Neurocrine Biosciences shares in Q4 2022, an estimated $1.72M.
Parallax Volatility Advisers first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 11 quarters.
Parallax Volatility Advisers's Neurocrine Biosciences position peaked at $2.01M in Q3 2021.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.